Haystack Oncology, a Quest Diagnostics (DGX) company, announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD to help optimize postoperative therapy decisions in patients with stage II/III non-small cell lung cancer, NSCLC. Rutgers Cancer Institute together with RWJBarnabas Health is the state’s only National Cancer Institute-designated Comprehensive Cancer Center.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics: Strong Growth Prospects and Operational Efficiency Justify Buy Rating
- Quest Diagnostics launches advanced pharmacogenomics offering
- Quest Diagnostics’ Strategic Expansion with Corewell Health Drives Buy Rating
- Quest Diagnostics and Corewell Health form joint venture in Michigan
- Figma initiated, Okta upgraded: Wall Street’s top analyst calls